MedTrace Logo

Study to Observe the Safety and Efficacy of Etanercept (Enbrel®) in Patients With Moderately Active Rheumatoid Arthritis in Every Day Clinical Practice in Austria

NCT01877239 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 111

Last updated 2018-12-03

Study results available
· View outcomes & findings →

Summary

This is a prospective non-interventional observational study to evaluate the treatment of moderately active RA patients in every day clinical practice in Austria. Patients will be observed over 52 weeks. The primary endpoint will be percentage of patients who reach CDAI remission after 24 weeks.

Conditions

Interventions

OTHER

non-intervention

observation of Etanercept treatment in moderately active RA patients in Austria. Etanercept treatment according to Austrian SmPC

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-12-10
Primary Completion
2016-01-07
Completion
2016-06-14

Countries

  • Austria

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01877239 on ClinicalTrials.gov